Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Christen Lykkegaard Andersen; Mads Emil Bjørn; Mary Frances McMullin; Claire Harrison; Jan Samuelsson; Elisabeth Ejerblad; Sonja Zweegman; Savio Fernandes; David Bareford; Steven Knapper; Eva Löfvenberg; Olle Linder; Bjørn Andreasson; Erik Ahlstrand; Morten Krogh Jensen; Ole Weis Bjerrum; Hanne Vestergaard; Herdis Larsen; Tobias Wirenfeldt Klausen; Torben Mourits-Andersen; Vibe Skov; Mads Thomassen; Torben Kruse; Kirsten Grønbæk; Hans Carl Hasselbalch

doi:10.1016/j.leukres.2014.04.002

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Christen Lykkegaard Andersen, Mads Emil Bjørn, Mary Frances McMullin, Claire Harrison, Jan Samuelsson, Elisabeth Ejerblad, Sonja Zweegman, Savio Fernandes, David Bareford, Steven Knapper, Eva Löfvenberg, Olle Linder, Bjørn Andreasson, Erik Ahlstrand, Morten Krogh Jensen, Ole Weis Bjerrum, Hanne Vestergaard, Herdis Larsen, Tobias Wirenfeldt Klausen, Torben Mourits-AndersenVibe Skov, Mads Thomassen, Torben Kruse, Kirsten Grønbæk, Hans Carl Hasselbalch

Institut for Klinisk Medicin

7 Citationer (Scopus)

Abstract

YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

Originalsprog	Engelsk
Tidsskrift	Leukemia Research
Vol/bind	38
Udgave nummer	7
Sider (fra-til)	816-821
Antal sider	6
ISSN	0145-2126
DOI	https://doi.org/10.1016/j.leukres.2014.04.002
Status	Udgivet - jul. 2014

Adgang til dokumentet

10.1016/j.leukres.2014.04.002

Citationsformater

Andersen, C. L., Bjørn, M. E., McMullin, M. F., Harrison, C., Samuelsson, J., Ejerblad, E., Zweegman, S., Fernandes, S., Bareford, D., Knapper, S., Löfvenberg, E., Linder, O., Andreasson, B., Ahlstrand, E., Jensen, M. K., Bjerrum, O. W., Vestergaard, H., Larsen, H., Klausen, T. W., ... Hasselbalch, H. C. (2014). Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research, 38(7), 816-821. https://doi.org/10.1016/j.leukres.2014.04.002

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. / Andersen, Christen Lykkegaard; Bjørn, Mads Emil; McMullin, Mary Frances et al.

I: Leukemia Research, Bind 38, Nr. 7, 07.2014, s. 816-821.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Andersen, CL, Bjørn, ME, McMullin, MF, Harrison, C, Samuelsson, J, Ejerblad, E, Zweegman, S, Fernandes, S, Bareford, D, Knapper, S, Löfvenberg, E, Linder, O, Andreasson, B, Ahlstrand, E, Jensen, MK, Bjerrum, OW, Vestergaard, H, Larsen, H, Klausen, TW, Mourits-Andersen, T, Skov, V, Thomassen, M, Kruse, T, Grønbæk, K & Hasselbalch, HC 2014, 'Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat', Leukemia Research, bind 38, nr. 7, s. 816-821. https://doi.org/10.1016/j.leukres.2014.04.002

@article{ec33aee4722f400ca4afa89721747928,

title = "Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat",

abstract = "YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.",

keywords = "Adipokines, Adult, Aged, Aged, 80 and over, C-Reactive Protein, Female, Histone Deacetylase Inhibitors, Humans, Hydroxamic Acids, Lectins, Male, Middle Aged, Polycythemia Vera, Thrombocythemia, Essential",

author = "Andersen, {Christen Lykkegaard} and Bj{\o}rn, {Mads Emil} and McMullin, {Mary Frances} and Claire Harrison and Jan Samuelsson and Elisabeth Ejerblad and Sonja Zweegman and Savio Fernandes and David Bareford and Steven Knapper and Eva L{\"o}fvenberg and Olle Linder and Bj{\o}rn Andreasson and Erik Ahlstrand and Jensen, {Morten Krogh} and Bjerrum, {Ole Weis} and Hanne Vestergaard and Herdis Larsen and Klausen, {Tobias Wirenfeldt} and Torben Mourits-Andersen and Vibe Skov and Mads Thomassen and Torben Kruse and Kirsten Gr{\o}nb{\ae}k and Hasselbalch, {Hans Carl}",

year = "2014",

month = jul,

doi = "10.1016/j.leukres.2014.04.002",

language = "English",

volume = "38",

pages = "816--821",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Pergamon Press",

number = "7",

}

TY - JOUR

T1 - Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

AU - Andersen, Christen Lykkegaard

AU - Bjørn, Mads Emil

AU - McMullin, Mary Frances

AU - Harrison, Claire

AU - Samuelsson, Jan

AU - Ejerblad, Elisabeth

AU - Zweegman, Sonja

AU - Fernandes, Savio

AU - Bareford, David

AU - Knapper, Steven

AU - Löfvenberg, Eva

AU - Linder, Olle

AU - Andreasson, Bjørn

AU - Ahlstrand, Erik

AU - Jensen, Morten Krogh

AU - Bjerrum, Ole Weis

AU - Vestergaard, Hanne

AU - Larsen, Herdis

AU - Klausen, Tobias Wirenfeldt

AU - Mourits-Andersen, Torben

AU - Skov, Vibe

AU - Thomassen, Mads

AU - Kruse, Torben

AU - Grønbæk, Kirsten

AU - Hasselbalch, Hans Carl

PY - 2014/7

Y1 - 2014/7

N2 - YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

AB - YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

KW - Adipokines

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - C-Reactive Protein

KW - Female

KW - Histone Deacetylase Inhibitors

KW - Humans

KW - Hydroxamic Acids

KW - Lectins

KW - Male

KW - Middle Aged

KW - Polycythemia Vera

KW - Thrombocythemia, Essential

U2 - 10.1016/j.leukres.2014.04.002

DO - 10.1016/j.leukres.2014.04.002

M3 - Journal article

C2 - 24836761

SN - 0145-2126

VL - 38

SP - 816

EP - 821

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater